Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha- and gamma-adaptin-binding protein (AAGAB) is a 34 kDa cytosolic protein found in most mammalian cells, characterized by two key regions: an N-terminal G-protein-like domain and a C-terminal dimerization domain (CTD). Its canonical function is as an assembly chaperone that facilitates the formation of AP-1 and AP-2 adaptor complexes, which are required for sorting proteins in clathrin-coated vesicle trafficking. AAGAB first exists as a homodimer; upon engaging AP-1 or AP-2 subunits (specifically the gamma subunit of AP-1, or the alpha subunit of AP-2), it dissociates into monomers to stabilize these subunits and enable complex assembly. Mutations in AAGAB, often leading to truncation and loss of the CTD, cause punctate palmoplantar keratoderma type I, a genetic skin disease characterized by hyperkeratotic lesions on palms and soles. AAGAB does not act as a classical therapeutic target (e.g., receptor, enzyme, transporter) and there are currently no known pharmacological agents or clinical biomarkers directly associated with its activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha- and gamma-adaptin-binding protein (AAGAB).